Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Erste Asset Management GmbH

Erste Asset Management GmbH grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,728,945 shares of the biotechnology company’s stock after purchasing an additional 43,000 shares during the period. Erste Asset Management GmbH owned approximately 2.60% of Sarepta Therapeutics worth $58,727,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. lifted its stake in Sarepta Therapeutics by 9.2% during the 4th quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock worth $254,167,000 after acquiring an additional 993,283 shares in the last quarter. Aberdeen Group plc lifted its stake in Sarepta Therapeutics by 13.6% during the 4th quarter. Aberdeen Group plc now owns 2,251,593 shares of the biotechnology company’s stock worth $48,454,000 after acquiring an additional 268,829 shares in the last quarter. First Trust Advisors LP lifted its stake in Sarepta Therapeutics by 209.1% during the 3rd quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock worth $37,380,000 after acquiring an additional 1,312,220 shares in the last quarter. Geode Capital Management LLC lifted its stake in Sarepta Therapeutics by 10.6% during the 4th quarter. Geode Capital Management LLC now owns 1,904,325 shares of the biotechnology company’s stock worth $40,990,000 after acquiring an additional 183,201 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Sarepta Therapeutics by 183.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock worth $33,627,000 after acquiring an additional 1,129,610 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

SRPT stock opened at $15.75 on Monday. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62. The firm has a market capitalization of $1.66 billion, a P/E ratio of -16.41, a P/E/G ratio of 0.17 and a beta of 0.21. The business’s 50-day moving average is $19.81 and its two-hundred day moving average is $19.82. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $43.92.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $2.18. The company had revenue of $730.80 million for the quarter, compared to analyst estimates of $474.16 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.Sarepta Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter last year, the company earned ($3.42) EPS. Analysts anticipate that Sarepta Therapeutics, Inc. will post 3.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

SRPT has been the topic of several research reports. Wells Fargo & Company decreased their target price on Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Deutsche Bank Aktiengesellschaft increased their target price on Sarepta Therapeutics from $12.00 to $14.00 and gave the stock a “sell” rating in a research note on Thursday, March 26th. Royal Bank Of Canada increased their target price on Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research note on Tuesday, April 7th. Oppenheimer reissued an “outperform” rating and set a $37.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Finally, Wedbush increased their target price on Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, March 26th. Eight equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $24.77.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the sale, the director owned 1,765 shares of the company’s stock, valued at $30,040.30. This trade represents a 80.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.90% of the stock is owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.